CDKN2A and hypopharyngeal carcinoma: Chen et al. observed a significant decrease in disease-free survival and disease-specific survival in patients with p16-negative oropharyngeal or hypopharyngeal carcinomas treated with RT or CRT and a high immunohistochemical expression of SLC2A1 [18].